Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q3 2022 · 10-Q
Revenue$35.23M$35.23M+26.7% vs Q3 2021 Net Income-$13.59M-$13.59MN/M vs Q3 2021 EPS Diluted-$0.46-$0.46N/M vs Q3 2021 Gross Profit$11,639,000+6.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived-$17,310,000N/M Free Cash Flowderived-$22,839,000N/M Margins · derivedGross margin33.0%−6.3 pt vs Q3 2021
Operating margin-27.4%−27.6 pt vs Q3 2021
Net margin-38.6%−13.5 pt vs Q3 2021
ended Feb 27, 2022 · filed Apr 7, 2022 · 39 d after period end